Nuclear Medicine World

Expandimos los horizontes en el uso de la medicina nuclear en Latinoamérica con herramientas de AI y recurso humano altamente capacitado.

[Michael Hofman @DrMHofman]

Getting ready for @ASCO #ASCO25? ✈️🔬

There’s lots of theranostics … including a dedicated session for prostate cancer.

Don’t miss these! 👀

[UroTarget @UroTarget]

The power of #teamwork.
Congratulations @dandanmena for the excellent presentation in ASCO GU 2025!!
@UroTeragLATAM @nmwlatam

[Cristian Udovicich @cristian_udo]

Is there a role for PSMA PET/CT in oligometatastic RCC?
Check out our @JournalofNucMed PEDESTAL study on PSMA-guided metastasis-directed therapy from @PeterMacCC @_ShankarSiva @DrMHofman

🧍33 pts & 60 metastases
🛜 93% radiotherapy
📖Median follow-up> 4y

✅Local control: 94% at 1y, 85% at 3y
✅Freedom from change (or commencement) of systemic therapy: 76% at 1y, 65% at 3y

[JNM @JournalofNucMed]

¹⁷⁷Lu-rhPSMA-10.1 is a promising next-generation radiopharmaceutical therapy for prostate cancer. Learn more: https://t.co/QUDDTBcXX9

#NuclearMedince #RPTherapy #ProstateCancer @NuclearMedEd

[Michael Hofman @DrMHofman]

... how common is PSMA-negative significant prostate
cancer? In the proPSMA study it was 3.3%

Hot of the press in @JournalofNucMed: https://t.co/S6phT0F03X

Wonderful work from @davcmed and team @pros_tic including @ButeauJames @declangmurphy

[Ken Herrmann @ProfKHerrmann]

Kicking off the inaugural edition of APCCC Diagnostics with two NEJM first authors … @veerukasi Prof. Jonas Hugosson. More to come over the next days. @APCCC_Lugano @stefanofanti4 @LoebStacy @Silke_Gillessen @DrMHofman @DrSpratticus @TylerSbrt @ProfHadaschik

[Confederación Americana de Urología (CAU) @CAU_URO]

10 BECAS DE INSCRIPCIÓN PARA EL UROTERAGLATAM 2025

“Asiste al evento Uro-Teragnóstico multidisciplinario más grande de Latinoamérica”

INSCRIPCIONES : https://t.co/YkH5biZkb2

CANCÚN CENTER – MÉXICO 11 Y 12 MARZO

BECAS : https://t.co/63WabfcjMD

[Michael Hofman @DrMHofman]

One year ago we published the @ANZUPtrials #TheraP follow-up... the Appendix contains the answers to many questions I am often asked. Three of my favourite Figures below:
1) Survival in patients who had FDG-discordant or low PSMA-expression and were not randomised vs. LuPSMA/cabazitaxel
2) Survival by PSA response. PSA≥90 had a hazard ratio of 0.34 !!
3) Prognostic power of FDG PET/CT (metabolic tumour volume) for survival - the single most powerful parameter

https://t.co/Ofl4B63opp
@MovemberAUS @PCF_Science

[Urooncologia.arg @oncourologiaarg]

🗞️ News! Asiste al evento Uro-Teragnóstico Multidisciplinario más grande de LATAM.

11 y 12 de marzo - Cancún 🇲🇽

🔥 40% de descuento para ex alumnos/as de nuestro curso o quienes se han inscripto este año. Solicita tu código.

Reserva tu lugar! 👉 https://t.co/PXI0EFscyN

[OncoAlert @OncoAlert]

Friends at #GU25 Inviting you to JOIN US at #APCCCDiagnostics25 🇨🇭in Lugano

A HYBRID Meeting (In Person & Live) Switzerland February 27-28, 2025

REGISTER: https://t.co/fatLEE63jn

ONLINE REGISTRATION FOR LMIC's FREE

OncoAlert 🚨Will be Live in Lugano with Coverage

In recent years, diagnostic capabilities for #ProstateCancer have significantly advanced through innovations in imaging, biomarkers, and the introduction of PSMA PET imaging, which have reshaped traditional diagnostic approaches. To address these advancements and their growing relevance in early detection, a new conference series, APCCC Diagnostics, will launch in February 2025 in Lugano, Switzerland, focusing on Prostate #Cancer diagnostics.

Scientific Committee
@ProfKHerrmann🇩🇪
@stefanofanti4 🇮🇹
@Silke_Gillessen 🇨🇭
@AOmlin 🇨🇭

Ambassadors
@ZilliThomas 🇨🇭
@nataliagandur 🇦🇷
@LoebStacy 🇺🇸
@bavilima 🇧🇷
@fabioturco92 🇨🇭
@DrYukselUrun 🇹🇷
@weoncologists 🇺🇸

The #APCCCDiagnostics Panel
@bjartell
@Albert0Briganti
@Ecastromarcos
@drlouiseemmett
@DrAGafita
@karolien_goffin
@ProfHadaschik
@DrMHofman
@Prof_Nick_James
@piet_ost
@gpalapa2
@MoniqueRoobol
@TylerSbrt
@DrSpratticus
@Tilki_De
@BertrandTOMBAL
@Nina18205
@UrsulaVogl
@ResearchWyatt

[Michael Hofman @DrMHofman]

Andrei Iagaru highlighting the relative cost of FDG, PSMA and Pluvicto. $2500 can $6500 vs $300,000 ! "I'm not a health economist but it seems FDG may be cost effective" #FelixFeng symposium @ASCO #GU25

[Michael Hofman @DrMHofman]

Lead-212 (²¹²Pb) DOTAMTATE could potentially offer a more effective targeted α-therapy treatment option for SSTR2-positive neuroendocrine tumours

https://t.co/y5ocR7UqAY

[Michael Hofman @DrMHofman]

SPECT deserves RESPECT!

@drlouiseemmett makes the argument that it is a powerful tool for theranostics ➤ enabling early, personalised treatment response evaluation ➤ optimizes outcomes by guiding therapy adjustments.
✓practical advantages over serial PET.

https://t.co/LLLOEVoDLh
@JournalofNucMed

[Jeremie Calais @CalaisJeremie]

Low- and High-Volume Disease in mHSPC:
from CHAARTED to #PSMA PET
#stagemigration
https://t.co/POmcfhRIzh
@UnterrainerLena @JournalofNucMed @thomashopemd @UCLAHealth @SathegkeM @AmarUKishan @CzerninJohannes @ProfKHerrmann @Wes_Armstrong_

[Michael Hofman @DrMHofman]

It's been a busy 2024 @pros_tic with clinical trials, discovery research & education all progressing at pace

We've put together a podcast of highlights:
https://t.co/lu4uMgcuDT

@PCF_Science

[JNM @JournalofNucMed]

A real-world comparison of cabazitaxel versus ¹⁷⁷Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer: https://t.co/FTMZGirhRd

#NuclearMedicine #RPTherapy #ProstateCancer @MarkusGraefen @carosiech

[ICPO Foundation @ICPO_Foundation]

ICPO Foundation and Prof. Richart P. Baum (@baumrp) applauds new radiotherapy and theranostics report of the Lancet Oncology Commission. Three ICPO SAB members @DrMHofman Michael Hofman, Mike Sathekge and Andrew Scott participated in the report.

[JNM @JournalofNucMed]

¹⁷⁷Lu-PSMA-617 showed antitumor activity and a favorable toxicity profile for patients with PSMA-positive mCRPC in a real-world setting. https://t.co/Oxw2MZ7UN5

#NuclearMedicine #ProstateCancer #RPTherapy @DrAGafita @radnucmp @MarkowskiGUOnc @AveryS32342

[Martín Angel @Martin_AngelMD]

Reserva la fecha 📆! Te esperamos en @IAF_Fleming

[MIM Software @mimsoftware]

MIM Software tiene el gusto de ser uno de los patrocinadores de esta serie educativa que exhibe las últimas inovaciones en #teragnóstico. Sintonice cada miércoles y aprenda más sobre PSMA, dosimetría en teranóstico y más. https://t.co/vrHxwktPNG